Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. | YCANTH (cantharidin, VP-102) | Common warts | Phase 3 | Enrollment Initiation | Topical | #N/A |
| Verrica Pharmaceuticals Inc. | TO-208 (VP-102) | Molluscum Contagiosum (molluscum) | Phase 3 | Data Released | Topical | N/A |
| Verrica Pharmaceuticals Inc. | VP-315 (LTX-315) | Basal cell carcinoma | Phase 2 | Data Released | Intratumoral | Oncology |
| Verrica Pharmaceuticals Inc. | VP-102 | Genital warts | Phase 2 | Topical | N/A | |
| Vertex Pharmaceuticals Incorporated | Povetacicept - (RUBY-3) | Autoimmune glomerulonephritis | BLA Filing | Data Released | Subcutaneous | Immunology |
| Vertex Pharmaceuticals Incorporated | CASGEVY | Sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) in patients aged 5-11 years | sNDA Filing | Ongoing | Intravenous | Hematology |
| Vertex Pharmaceuticals Incorporated | TRIKAFTA | Cystic fibrosis in patients one year to less than two years of age | sNDA Filing | Ongoing | Oral | Respiratory |
| Vertex Pharmaceuticals Incorporated | inaxaplin (VX-147) - (AMPLITUDE) | Proteinuric kidney disease with two mutations in the APOL1 gene (AMKD) | Phase 3 | Ongoing | oral | Genetic Disorder |
